Danaher Corporation

NYSE DHR

Download Data

Danaher Corporation Shareholders' Equity and Liabilities 5 year CAGR for the quarter ending March 31, 2024: 10.00%

Danaher Corporation Shareholders' Equity and Liabilities 5 year CAGR is 10.00% for the quarter ending March 31, 2024, a -20.10% change year over year. Shareholders' Equity and Liabilities is the sum of shareholders' equity and total liabilities, representing the company's sources of funding. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Danaher Corporation Shareholders' Equity and Liabilities for the quarter ending March 31, 2023 was USD 85.04 B, a 1.98% change year over year.
  • Danaher Corporation Shareholders' Equity and Liabilities for the quarter ending March 31, 2022 was USD 83.39 B, a 10.56% change year over year.
  • Danaher Corporation Shareholders' Equity and Liabilities for the quarter ending March 31, 2021 was USD 75.43 B, a 9.42% change year over year.
  • Danaher Corporation Shareholders' Equity and Liabilities for the quarter ending March 31, 2020 was USD 68.93 B, a 33.14% change year over year.
NYSE: DHR

Danaher Corporation

CEO Mr. Steven M. Rales
IPO Date Jan. 5, 1979
Location United States
Headquarters 2200 Pennsylvania Avenue, NW, Washington, DC, United States, 20037-1701
Employees 61,000
Sector Healthcare
Industry Diagnostics & research
Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Similar companies

A

Agilent Technologies Inc

NA

NA

IDXX

IDEXX Laboratories Inc

NA

NA

WAT

Waters Corporation

NA

NA

CRL

Charles River Laboratories

NA

NA

RVTY

Revvity Inc.

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email